GoAI
Get started
Modalis Therapeutics Corporation logo

Modalis Therapeutics Corporation

4883.T

JPXHealthcareBiotechnology

Open in GoAI

Latest quote

¥33.00

¥0.00 · 0.00%

Aug 24, 3:30 PM JST

4883.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic modulation of specific genetic loci. Modalis also has a collaborative research agreement with JCR Pharmaceuticals Co., Ltd., aimed at assessing gene therapy drug delivery methods for the central nervous system (CNS), particularly for CNS-related disorders. Founded in 2016, the company was initially known as EdiGENE Corporation before changing its name to Modalis Therapeutics Corporation in August 2019. Its operations are based in Tokyo, Japan.

Industry
Biotechnology
Sector
Healthcare
Headquarters
JP
CEO
Haruhiko Morita
Listed since
Aug 3, 2020
Employees
17

Market position

52-week range

Current ¥33.00

Open
¥33.00
Previous close
¥33.00
Volume
98.7K
0.03× average
Average volume
3.37M
Average daily volume
Market cap
3.18B JPY
Beta
0.39
Market reference 1
50-day average
¥32.74
+0.79% above average
200-day average
¥52.37
-36.99% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.51B JPY
P/E (TTM)
-1.37×
P/B (TTM)
1.26×
P/S (TTM)
0×
EV / EBITDA
-0.68×
Earnings yield
-49.75%
Free cash flow yield
-49.01%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-77.07%
Return on assets
-72.62%
Return on invested capital
-78.17%

Financial health

Debt / equity
0.11×
Current ratio
21.46×
Altman Z-score
1.16
Piotroski F-score
1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends11378%-33733%-78844%-123954%Gross margin, FY2021: 100.00%Gross margin, FY2022: -205.37%Operating margin, FY2021: -112676.73%Operating margin, FY2022: -5094.31%Net margin, FY2021: -67177.82%Net margin, FY2022: -6673.36%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 -205.37%. Operating margin FY2021 -112676.73%. Operating margin FY2022 -5094.31%. Net margin FY2021 -67177.82%. Net margin FY2022 -6673.36%.

Income trends

Revenue

40.5M JPY+3581.82%

Operating income

−2.21B JPY-65.35%

Net income

−2.15B JPY-63.34%
Income trends across reported periods314.82M JPY−782.46M JPY−1.88B JPY−2.98B JPYRevenue, FY2021: 1.1M JPYRevenue, FY2022: 40.5M JPYOperating income, FY2021: −1.24B JPYOperating income, FY2022: −2.06B JPYOperating income, FY2023: −2.37B JPYOperating income, FY2024: −1.34B JPYOperating income, FY2025: −2.21B JPYNet income, FY2021: −738.96M JPYNet income, FY2022: −2.7B JPYNet income, FY2023: −2.39B JPYNet income, FY2024: −1.32B JPYNet income, FY2025: −2.15B JPYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.1M JPY. Revenue FY2022 40.5M JPY. Operating income FY2021 −1.24B JPY. Operating income FY2022 −2.06B JPY. Operating income FY2023 −2.37B JPY. Operating income FY2024 −1.34B JPY. Operating income FY2025 −2.21B JPY. Net income FY2021 −738.96M JPY. Net income FY2022 −2.7B JPY. Net income FY2023 −2.39B JPY. Net income FY2024 −1.32B JPY. Net income FY2025 −2.15B JPY.
Metric (JPY)FY2025FY2024FY2023FY2022FY2021
Revenue———40.5M JPY1.1M JPY
Cost of goods sold——731K JPY123.68M JPY—
Gross profit——−731K JPY−83.18M JPY1.1M JPY
Research and development1.98B JPY1.9B JPY2.1B JPY1.86B JPY1.01B JPY
Selling, general, and administrative231.81M JPY220M JPY267.81M JPY241.99M JPY231.02M JPY
Operating expenses2.21B JPY1.34B JPY2.37B JPY2.1B JPY1.24B JPY
Interest income3.85M JPY102K JPY25K JPY57K JPY57K JPY
Interest expense2.8M JPY9.16M JPY4.41M JPY——
Depreciation and amortization—731K JPY731K JPY123.68M JPY77.87M JPY
Operating income−2.21B JPY−1.34B JPY−2.37B JPY−2.06B JPY−1.24B JPY
Net income−2.15B JPY−1.32B JPY−2.39B JPY−2.7B JPY−738.96M JPY

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
0%
0 beats, 1 miss, 0 met estimates
Average EPS surprise
-40883.33%
1 comparable report
Latest EPS result
-6.32

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates-1.16-4.38-7.61-10.83Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Nov 7, 2024: actual -6.09, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 13, 2025: actual -1.36, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 8, 2025: actual -9.02, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 7, 2025: actual -4.76, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 7, 2025: actual -10.13, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 12, 2026: actual -3.95, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 13, 2026: actual -3.64, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 10, 2026: actual -6.32, estimate —, surprise —, Comparison unavailable.

4883.T peers

Chugai Pharmaceutical Co., Ltd. logo

4519.T

Chugai Pharmaceutical Co., Ltd.

¥6,987

-0.34%

Takeda Pharmaceutical Company Limited logo

4502.T

Takeda Pharmaceutical Company Limited

¥5,797

+0.57%

HOYA Corporation logo

7741.T

HOYA Corporation

¥24,895

0.00%

Otsuka Holdings Co., Ltd. logo

4578.T

Otsuka Holdings Co., Ltd.

¥12,210

+0.12%

Daiichi Sankyo Company, Limited logo

4568.T

Daiichi Sankyo Company, Limited

¥2,858

+0.86%

Astellas Pharma Inc. logo

4503.T

Astellas Pharma Inc.

¥2,406.5

+0.82%

Continue in GoAI

Research 4883.T

research.disclaimer